^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MTOR mutation

    i
    Other names: Mechanistic Target Of Rapamycin Kinase, Mammalian Target Of Rapamycin, Rapamycin And FKBP12 Target 1, FK506-Binding Protein 12-Rapamycin Complex-Associated Protein 1, Mechanistic Target Of Rapamycin (Serine/Threonine Kinase), FK506 Binding Protein 12-Rapamycin Associated Protein 2, FKBP12-Rapamycin Complex-Associated Protein 1, Serine/Threonine-Protein Kinase MTOR, Rapamycin Associated Protein FRAP2, FKBP-Rapamycin Associated Protein, Mechanistic Target Of Rapamycin, Rapamycin Target Protein 1,
    Entrez ID:
    2475
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    1year
    Not all TMB-high are created equal & predict for #immunotherapy efficacy. In GI cancers with MSS & TMB-high, mutations in SMAD2, MTOR, NFE2L2, RB1, KEAP1, TERT, & RASA1 were associated with suppressed tumor immune environment. https://t.co/YtBonLmOZs (@jsoriamd)
    Clinical • IO biomarker
    |
    TMB (Tumor Mutational Burden) • RB1 (RB Transcriptional Corepressor 1) • KEAP1 (Kelch Like ECH Associated Protein 1) • mTOR (Mechanistic target of rapamycin kinase) • RASA1 (RAS P21 Protein Activator 1) • SMAD2 (SMAD Family Member 2)
    |
    TMB-H • MTOR mutation
    2years
    TSC/mTOR mutations are not specific for any tumor type - eagerly awaiting the WHO approach to the molecularly defined renal tumors! @GU_Path_Society #USCAP2022 #USCAP22 (@SaraEWobker)
    mTOR (Mechanistic target of rapamycin kinase) • SKAP2 (Src Kinase Associated Phosphoprotein 2)
    |
    MTOR mutation
    almost3years
    ⭐️Dual inhibition of BRAF and mTOR in BRAFV600E-mutant pediatric, adolescent, and young adult brain tumors 1/2 @ShirajSenMDPhD @CSHL @molcasestud @OncoAlert https://t.co/tLSosPi8ve (@VivekSubbiah)
    Clinical
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • MTOR mutation
    almost3years
    ESC-RCC, AE1/AE3, TSC1/TSC2 mutation. EVT, CK7, TSC/mTOR mutation (@SumantaDas_7)
    mTOR (Mechanistic target of rapamycin kinase) • TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
    |
    TSC1 mutation • TSC2 mutation • MTOR mutation
    3years
    Everolimus-low response rate (7%) in pan-cancer mutation+ (TSC1, TSC2, TSC1+TSC2, mTOR) basket study (n=30)-1 of 2 with response had upper tract #urothelialcarcinoma with biallelic TSC1 alteration + high TMB: @danafarber @sloan_kettering #DrKwiatkowski https://t.co/OYkmMUWhwD (@sonpavde)
    Pan tumor
    |
    TMB (Tumor Mutational Burden) • mTOR (Mechanistic target of rapamycin kinase) • TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
    |
    TMB-H • TSC1 mutation • TSC2 mutation • MTOR mutation
    |
    everolimus
    over3years
    CSHLP Mol Case Stud 👉🏼Dual inhibition of BRAF and mTOR in BRAFV600E-mutant pediatric, adolescent, and young adult brain tumors https://t.co/vi6stbTC1v (@VivekSubbiah)
    Clinical
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • MTOR mutation
    over3years
    ⭐️🚨Dual inhibition of BRAF and mTOR in BRAFV600E-mutant pediatric, adolescent, and young adult brain tumors @CSHL @molcasestud @ShirajSenMDPhD @OncoAlert #Ayacsm #braintumor https://t.co/tRSvXpYgoG (@VivekSubbiah)
    Clinical
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • MTOR mutation
    over3years
    6. Dual inhibition of BRAF and mTOR in BRAF V600E -mutant pediatric, adolescent, and young adult brain tumors @ShirajSenMDPhD @molcasestud @CSHL https://t.co/YcXnqCyqlN (@VivekSubbiah)
    Clinical
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • MTOR mutation